Ertan Eryilmaz
Vice President, Biologics InduPro
Ertan Eryilmaz, Ph.D., is the Vice President of Biologics at InduPro, leading the Molecular Discovery Engineering and Protein Sciences teams and shaping the company’s therapeutic discovery strategy. He specializes in antibody discovery, protein engineering, and advancing biologics from target identification to IND. Prior to InduPro, he led Biologics at Xilio Therapeutics and held key scientific and leadership roles at Takeda Oncology, Agensys/Astellas, and Boehringer Ingelheim. His work contributed to multiple clinical programs, including PADCEV and several bispecific antibody platforms.
Seminars
Tuesday 9th June 2026
From Proximity Mapping to Therapeutics: Rational Target-Pair Selection With the MINTTM Platform for Bispecific ADCs
9:00 am
- Explore how MINT™ maps cell-surface protein microenvironments using proximity proteomics and machine learning to identify novel, co-localized target pairs for precision therapeutics
- Outline how applying MINT™ enables rational selection of tumor-associated proximity antigens (TAPAs), guiding the design of bispecific ADCs with improved tumor selectivity and reduced off-target engagement
- Analyze how this proximity-driven framework supports the discovery and optimization of multiple bispecific ADC candidates, providing a systematic path from target-pair identification to preclinical validation
Thursday 11th June 2026
Exploring How Cis-Acting PD-1 Bispecific Antibodies Enable Tunable Checkpoint Modulation Through Immune Synapse Sequestration or Recruitment
9:00 am
- Outline the cis-acting PD-1 bispecific framework that enables programmable checkpoint modulation by controlling PD-1 spatial positioning at the immune synapse through defined molecular geometry
- Exploring how this design strategy supports both antagonist and agonist outcomes, linking synapse exclusion or recruitment of PD-1 to distinct signaling states and T-cell functional programs without Fc receptor dependence
- Discussing how this approach establishes a unified path from molecular design and epitope selection to disease-relevant immune modulation across oncology and autoimmune models
